Lipid bilayer coatings for rapid enzyme-linked immunosorbent assay
Source abstract
Abstract
The enzyme-linked immunosorbent assay (ELISA) is a widely used method for protein detection and relies on the specific capture of target proteins while minimizing the nonspecific binding of other interfering proteins and biomolecules. To prevent nonspecific binding events, blocking agents such as bovine serum albumin (BSA) protein, mixtures of proteins in media such as milk or serum, and/or surfactants are typically added to ELISA plates after probe attachment and before analyte capture. Herein, we developed a streamlined ELISA strategy in which readily prepared lipid nanoparticles are utilized as the blocking agent and are added together with the probe molecule to the ELISA plate, resulting in fewer processing steps, quicker protocol time, and superior detection performance compared to conventional BSA blocking. These measurement capabilities were established for coronavirus disease-2019 (COVID-19) antibody detection in saline and human serum conditions and are broadly applicable for developing rapid ELISA diagnostics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Biosensors and Analytical Detection · Advanced biosensing and bioanalysis techniques · Advanced Biosensing Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (26)
Show source-provided references
1. Crowther · 2001
2. Advantages, disadvantages and modifications of conventional ELISA
3. Non-Specific Adsorption Reduction Methods in Biosensing10.3390/s19112488 ↗
4. Antifouling strategies in advanced electrochemical sensors and biosensors10.1039/C9AN02017A ↗
5. Quantitation of the blocking effect of tween 20 and bovine serum albumin in ELISA microwells10.1006/abio.2000.4602 ↗
6. A new interpretation of serum albumin surface passivation10.1021/la034870g ↗
7. Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum albumin (BSA)—not all BSAs are alike10.1016/j.jim.2012.06.009 ↗
8. Lipid-based passivation in nanofluidics10.1021/nl204535h ↗
9. Lipid-bicelle-coated microfluidics for intracellular delivery with reduced fouling10.1021/acsami.0c11485 ↗
10. Supported lipid bilayer formation: beyond vesicle fusion10.1021/acs.langmuir.9b03706 ↗
11. Antibody conjugated supported lipid bilayer for capturing and purification of viable tumor cells in blood for subsequent cell culture10.1016/j.biomaterials.2013.03.096 ↗
12. A lipid-nanopillar-array-based immunosorbent assay
13. Post-assembly filling of supported lipid bilayers by soluble lipid derivatives10.1002/bkcs.10873 ↗
14. Zwitteration: coating surfaces with zwitterionic functionality to reduce nonspecific adsorption10.1021/la500057j ↗
15. Supported lipid bilayer formation from phospholipid-fatty acid bicellar mixtures10.1021/acs.langmuir.0c00675 ↗
16. Optimizing the formation of supported lipid bilayers from bicellar mixtures10.1021/acs.langmuir.7b00210 ↗
17. Influence of NaCl concentration on bicelle-mediated SLB formation10.1021/acs.langmuir.9b01644 ↗
18. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease
19. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
20. Conformational flexibility of fatty acid-free bovine serum albumin proteins enables superior antifouling coatings10.1038/s43246-020-0047-9 ↗
21. Understanding protein adsorption phenomena at solid surfaces10.1016/j.cis.2010.12.007 ↗
22. A bottom-up approach to understanding protein layer formation at solid–liquid interfaces10.1016/j.cis.2013.12.006 ↗
23. Quantitative measurement of IgG to severe acute respiratory syndrome coronavirus-2 proteins using immunocap10.1159/000514203 ↗
24. A blocking agent and a blocking step are not needed in ELISA, immunostaining dot-blots and western blots10.1016/0022-1759(89)90129-4 ↗
25. BSA blocking in enzyme-linked immunosorbent assays is a non-mandatory step: a perspective study on mechanism of BSA blocking in common ELISA protocols10.1039/C5RA20750A ↗
26. Future considerations for the mRNA-lipid nanoparticle vaccine platform10.1016/j.coviro.2021.03.008 ↗